Crystalline forms of r-(r*,r*)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-(phenylamino)carbonyl-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
CA 2521993 A1 · Owner: Vlahova, Petinka Ivanova · Inventors: Morrison, Henry Grant, Ii; Vlahova, Petinka Ivanova; Coates, David Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Novel crystalline forms of R-(R*,R*)-2-(4-fluorophenyl)-.beta. .DELTA.;dihydroxy-5-(1-, methylethyl)-3-phenyl-4-(phenylamino)carbonyl-1H-pyrrole-1-heptanoic acid hemi, calcium salt atorvastatin designated Form V Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV Form XV, Form XVI, Form XVII, Form, XVIII and Form XIX are characterized by their X-ray powder diffraction solid-, state NMR, and/or Raman spectroscopy are described as well as methods for the , preparation and pharmaceutical composition of the same which are useful as agents for , treating hyperlipidemia, hypercholesterolemia, osteoporosis and Alzheimer's disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 21, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 21, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 21, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.